Pharvaris (NASDAQ:PHVS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pharvaris (NASDAQ:PHVS) from a sell rating to a hold rating in a research report released on Saturday.

A number of other research analysts have also issued reports on the stock. Morgan Stanley boosted their price target on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Bank of America boosted their target price on Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Thursday, December 4th. Leerink Partners set a $38.00 target price on Pharvaris in a research note on Wednesday, December 3rd. Finally, Guggenheim raised their price target on Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.70.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $27.29 on Friday. Pharvaris has a one year low of $11.51 and a one year high of $29.80. The company has a market cap of $1.48 billion, a P/E ratio of -8.50 and a beta of -2.78. The firm has a fifty day moving average of $26.95 and a two-hundred day moving average of $25.29.

Institutional Trading of Pharvaris

A number of institutional investors have recently added to or reduced their stakes in the stock. General Atlantic L.P. grew its position in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC lifted its position in shares of Pharvaris by 8.3% during the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC boosted its stake in shares of Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after acquiring an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. boosted its stake in shares of Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after acquiring an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP grew its holdings in shares of Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.